HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Sohy, C. Articles by Sibille, Y. Search for Related Content PubMed PubMed Citation Articles by Sohy, C. Articles by Sibille, Y.

Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: what studies are still needed?

¹ Pulmonary Section and ² Experimental Medicine Unit, Christian de Duve Institute of Cellular Pathology, University of Louvain, Belgium. ³ Pulmonary and Critical Care Medicine, Winthrop-University Hospital and State University of New York at Stony Brook, NY, USA

CORRESPONDENCE: Y. Sibille, Service de Pneumologie, Cliniques Universitaires de Mont-Godinne, Université catholique de Louvain, B-5530, Yvoir, Belgium. Fax: 32 81423352. E-mail: sibille@mexp.ucl.ac.be

Keywords: antibiotics, chronic obstructive pulmonary disease, respiratory infection, viruses

Received: November 5, 2001
Accepted November 6, 2001

Abstract

The use of antibiotics in acute exacerbations of chronic bronchitis (AECBs) remains the subject of controversy despite considerable medical and socioeconomic implications.

First, the contribution of bacterial infection to AECBs is difficult to assess in patients with chronic obstructive pulmonary disease (COPD) who are chronically colonized with respiratory pathogens. In addition, several studies suggest a major role of viral infections in AECBs.

Secondly, it is unlikely that all COPD patients will benefit from antibiotics during AECBs. In particular, the benefit in mild COPD remains uncertain. Unfortunately, the number of studies complying with evidence-based medicine requirements is too small for definite recommendations in AECBs to be drawn up.

Considering the impact of acute exacerbations of chronic bronchitis on chronic obstructive pulmonary disease patients, as well as the community, and the impact of antibiotic therapy on the development of bacterial resistance, there is an urgent need for the design of appropriate multicentric studies to define the usefulness of this type of treatment in acute exacerbations of chronic bronchitis.

This article has been cited by other articles:

				M.N. de Melo, P. Ernst, and S. Suissa Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Eur. Respir. J., May 1, 2004; 23(5): 692 - 697. [Abstract] [Full Text] [PDF]

				C. Pilette, S. R. Durham, J.-P. Vaerman, and Y. Sibille Mucosal Immunity in Asthma and Chronic Obstructive Pulmonary Disease: A Role for Immunoglobulin A? Proceedings of the ATS, April 1, 2004; 1(2): 125 - 135. [Abstract] [Full Text] [PDF]